EFR reports its Q1 2026 earnings today against a backdrop of dramatic price momentum — the stock has rallied 30% over the past month and nearly 20% in a single week, a surge that dwarfs most of its uranium peers heading into the announcement.
The price move has not been matched by a surge in short-seller conviction. Short interest runs at a modest 2.8% of free float, and borrow availability remains well-supplied, with costs barely above 0.9% annualised. Availability has tightened somewhat — now at roughly 74% of short interest, up from 60% at the start of May, suggesting a small step-up in demand for borrows as the stock rallied — but there is no sign of a lending squeeze. Days to cover clock in at 6.5, with the utilisation rank in just the 5th percentile of the universe, a reading that points to a borrow market far from stressed.
The earnings context is more nuanced. The full-year 2025 results, reported in February, showed a deeper net loss of $85.6 million compared with $47.8 million a year earlier, on revenue that slipped to $65.9 million from $78.1 million. The Q1 2026 print already released yesterday shows EPS of $(0.04) against a $(0.02) estimate — a miss on the bottom line — while revenue of $35.8 million beat one estimate of $32 million but fell short of another at $43.4 million. The picture is therefore mixed: the company is burning cash in the near term while revenue beats are possible depending on the analyst's benchmark. Energy Fuels sits in the 85th percentile for historical EPS surprise, meaning beats have been more the rule than the exception over time — a useful framing, even if the Q1 figure itself disappointed on the headline loss.
What makes EFR interesting is the structural story underpinning the rally. The company holds uranium, rare earth, and vanadium assets at a moment when Western governments are scrambling for non-Chinese critical mineral supply. The stock has outperformed correlated peers sharply: CCO fell 3% on the day and nearly 2% on the week, DML dropped 4% on both timeframes, and NXE slid 2.7% — yet EFR climbed 11.7% in a single session. Institutional holders have been adding exposure, with Vanguard, BlackRock, and Mirae Asset all reporting increased positions in recent filings; Vanguard alone added more than 3 million shares. Insiders have been sellers on the other side, with a VP and an independent director trimming positions in March and April at prices well below current levels — though the significance scores on those trades were low.
The Q1 call scheduled for today will test whether EFR's revenue trajectory and uranium sales volumes can justify a valuation that carries a deeply negative earnings yield and an EV/EBITDA multiple that, while compressing sharply over the past month, remains near 250x.
See the live data behind this article on ORTEX.
Open EFR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
